Details for Patent: 6,750,237
✉ Email this page to a colleague
Title: | Pharmaceutical formulations containing zolmitriptan |
Abstract: | A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders. |
Inventor(s): | Dearn; Alan Roy (Ware, GB), Williamson; Sarah Louise (Ware, GB), Summers; Simon John (Ware, GB), Coomber; Trevor John (Ware, GB) |
Assignee: | AstraZeneca AB (London, GB) |
Filing Date: | Aug 28, 2002 |
Application Number: | 10/129,773 |
Claims: | 1. A pharmaceutical formulation suitable for intranasal administration which comprises zolmitriptan and a pharmaceutically acceptable carrier wherein the pH of the formulation is in the range 4.5 to 5.5. 2. A pharmaceutical formulation according to claim 1 wherein the pH of the formulation is 5. 3. A pharmaceutical formulation according to claim 1 wherein the formulation is buffered. 4. A pharmaceutical formulation according to claim 2 wherein the formulation is buffered. 5. A pharmaceutical formulation according to claim 1 which is sterile. 6. A pharmaceutical formulation according to claim 2 which is sterile. 7. A pharmaceutical formulation according to claim 3 which is sterile. 8. A pharmaceutical formulation according to claim 4 which is sterile. 9. A pharmaceutical formulation suitable for intranasal administration which comprises zolmitriptan and a pharmaceutically acceptable carrier wherein the pH of the formulation is less than 7.0, wherein the formulation is buffered by a mixture of citric acid and disodium phosphate. 10. A pharmaceutical formulation according to claim 9 which is sterile. 11. A pharmaceutical formulation suitable for intranasal administration which comprises zolmitriptan and a pharmaceutically acceptable carrier wherein the pH of the formulation is in the range 4.5 to 5.5, wherein the formulation is buffered by a mixture of citric acid and disodium phosphate. 12. A pharmaceutical formulation according to claim 11 which is sterile. 13. An intranasal administration device containing a pharmaceutical formulation as defined in any one of claims 1, 2, 9 or 11. 14. The intranasal administration device of claim 13, wherein the pharmaceutical formulation is packaged to protect the formulation from light. 15. An aqueous solution of zolmitriptan in a buffer at a pH in the range of 4.5 to 5.5. 16. The aqueous solution of claim 15, wherein the pH is 5. |